Nuvectra Corp (NASDAQ:NVTR) Receives Consensus Rating of “Buy” from Analysts
Nuvectra Corp (NASDAQ:NVTR) has been given a consensus rating of “Buy” by the six analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $8.75.
Several research firms have recently issued reports on NVTR. Piper Jaffray Companies decreased their target price on Nuvectra from $18.00 to $4.00 and set an “overweight” rating for the company in a research report on Thursday, August 1st. JMP Securities decreased their target price on Nuvectra to $10.00 and set an “outperform” rating for the company in a research report on Thursday, August 1st. They noted that the move was a valuation call. ValuEngine upgraded Nuvectra from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research upgraded Nuvectra from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research report on Wednesday, July 10th.
In other Nuvectra news, insider Benjamin Tranchina acquired 8,500 shares of the business’s stock in a transaction dated Wednesday, May 22nd. The shares were acquired at an average price of $4.25 per share, for a total transaction of $36,125.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, President Joseph Paul Hanchin sold 7,900 shares of Nuvectra stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $3.98, for a total value of $31,442.00. The disclosure for this sale can be found here. Insiders own 2.90% of the company’s stock.
Shares of Nuvectra stock traded down $0.10 during trading on Wednesday, hitting $1.60. 177,098 shares of the company were exchanged, compared to its average volume of 303,524. The company has a market capitalization of $28.62 million, a price-to-earnings ratio of -0.50 and a beta of 0.71. Nuvectra has a 1-year low of $1.56 and a 1-year high of $25.17. The stock has a fifty day moving average price of $2.40. The company has a debt-to-equity ratio of 0.58, a current ratio of 4.86 and a quick ratio of 4.42.
Nuvectra (NASDAQ:NVTR) last posted its earnings results on Wednesday, July 31st. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.81) by $0.19. The company had revenue of $12.35 million during the quarter, compared to analyst estimates of $12.42 million. Nuvectra had a negative return on equity of 58.23% and a negative net margin of 99.08%. Sell-side analysts predict that Nuvectra will post -2.44 EPS for the current year.
Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.
Further Reading: What is an Initial Public Offering (IPO)?
Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.